Literature DB >> 24605225

Lentivirus vector-mediated Rho guanine nucleotide dissociation inhibitor 2 induces beta-2 adrenergic receptor desensitization in β2AR desensitization mice model.

Songshi Ni1, Jing Zhao1, Zhenxue Fu1, Hua Liu1.   

Abstract

BACKGROUND: It is well-known that chronic administration of β2AR agonists can induce β2AR desensitization. Our previous study showed that Rho guanine nucleotide dissociation inhibitor 2 (RhoGDI2) overexpression induced beta-2 adrenergic receptor (β2AR) desensitization in airway smooth muscle cells. The purpose of this study was to further study the function of RhoGDI2 in β2AR desensitization by β2AR desensitization mouse model.
METHODS: Studies were performed using a β2AR desensitization mice model induced by salbutamol. The mice were randomly divided into five groups (n=45): RhoGDI2 overexpression group (n=10); RhoGDI2 siRNA group (n=10); empty viral vector group (n=10); experimental control group (n=10); blank control group-without any drug treatment (n=5). The first four groups were used the same methods and the same dose to establish β2AR desensitization mice model by salbutamol. The first three groups that salbutamol-treated were used for intratracheal delivery of lentiviral vectors. Airway hyperreactivity was measured through a whole-body plethysmograph system. RhoGDI2, β2AR, GRK2 mRNA and protein expression levels were then detected by RT-PCR and western blot analyses in fresh lung tissues. As well as the activity of GRK was assessed by light-dependent phosphorylation of rhodopsin.
RESULTS: We successfully constructed β2AR desensitization mouse model. As expected, airway responsiveness after inhaling acetylcholine chloride (Ach) was markedly increased in the RhoGDI2 overexpression group compared to experimental control group and blank control group when concentrations of Ach was 45 mg/mL (all P<0.05), while, it was markedly decreased in the RhoGDI2 siRNA group compared to experimental control group (P<0.05). RhoGDI2, GRK2 expressions and GRK enzymatic activity were significantly increased in RhoGDI2 overexpression group compared to experimental control group and blank control group (all P<0.05). RhoGDI2, GRK2 expressions and GRK enzymatic activity were significantly decreased in RhoGDI2 siRNA group compared to experimental control group and blank control group (all P<0.05). Conversely, β2AR expression were significantly lower in RhoGDI2 overexpression group compared to experimental control group and blank control group (all P<0.05), exhibiting an inverse correlation with RhoGDI2 expression.
CONCLUSIONS: To sum up, our present studies found that RhoGDI2 might induce β2AR desensitization and GRK2 might take part in RhoGDI2-mediated β2AR desensitization.

Entities:  

Keywords:  GRK2; Rho guanine nucleotide dissociation inhibitor 2 (RhoGDI2); lentivirus vector; β2AR desensitization

Year:  2014        PMID: 24605225      PMCID: PMC3944182          DOI: 10.3978/j.issn.2072-1439.2013.12.49

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  27 in total

Review 1.  GDIs: central regulatory molecules in Rho GTPase activation.

Authors:  Céline DerMardirossian; Gary M Bokoch
Journal:  Trends Cell Biol       Date:  2005-07       Impact factor: 20.808

2.  RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.

Authors:  Hee Jun Cho; Kyoung Eun Baek; Sun-Mi Park; In-Kyu Kim; In-Koo Nam; Yeong-Lim Choi; Seung-Ho Park; Min-Ju Im; Jungil Choi; Jinhyun Ryu; Jae Won Kim; Chang Won Lee; Sang Soo Kang; Jiyun Yoo
Journal:  Cancer Lett       Date:  2011-06-24       Impact factor: 8.679

Review 3.  Past, present and future--beta2-adrenoceptor agonists in asthma management.

Authors:  Malcolm R Sears; Jan Lötvall
Journal:  Respir Med       Date:  2005-02       Impact factor: 3.415

Review 4.  RhoGDI signaling provides targets for cancer therapy.

Authors:  Michael A Harding; Dan Theodorescu
Journal:  Eur J Cancer       Date:  2010-03-27       Impact factor: 9.162

5.  Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis.

Authors:  Huiyan Niu; Hui Li; Can Xu; Ping He
Journal:  Oncol Rep       Date:  2010-08       Impact factor: 3.906

6.  Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins.

Authors:  Deborah J Watson; Gary P Kobinger; Marco A Passini; James M Wilson; John H Wolfe
Journal:  Mol Ther       Date:  2002-05       Impact factor: 11.454

7.  Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.

Authors:  Liya Ma; Gaixiang Xu; Anna Sotnikova; Monika Szczepanowski; Maciej Giefing; Kristina Krause; Matthias Krams; Reiner Siebert; Jie Jin; Wolfram Klapper
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

8.  Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.

Authors:  Dan Theodorescu; L M Sapinoso; M R Conaway; G Oxford; G M Hampton; H F Frierson
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

9.  Increased RhoGDI2 and peroxiredoxin 5 levels in asthmatic murine model of beta2-adrenoceptor desensitization: a proteomics approach.

Authors:  Hua Liu; Lin-fu Zhou; Qian Zhang; Fen-hong Qian; Kai-sheng Yin; Mao Huang; Xi-long Zhang
Journal:  Chin Med J (Engl)       Date:  2008-02-20       Impact factor: 2.628

10.  beta2-adrenergic receptor signaling and desensitization elucidated by quantitative modeling of real time cAMP dynamics.

Authors:  Jonathan D Violin; Lisa M DiPilato; Necmettin Yildirim; Timothy C Elston; Jin Zhang; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2007-11-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.